Endurance Exercise Improves Skeletal Muscle Microvasculature in Patients With Sickle Cell Disease
Patients who underwent moderate-intensity endurance training experienced improvements in capillary density and number of capillaries around a fiber.
Sickle Cell Disease
Cell Therapy Transplant Approach Holds Early Promise for Patients With Sickle Cell Disease
Researchers assessed a method of extracting marrow cells and transforming them to promote fetal hemoglobin generation in patients with sickle cell disease.
Clinician Attitudes About Discussing Hematopoietic Cell Transplantation for Sickle Cell Disease
Clinicians reported informing only 42% of families about hematopoietic cell transplantation, citing concerns about safety and cost.
Adakveo Approved for Sickle Cell Disease
The FDA has approved Adakveo (crizanlizumab-tmca; Novartis) to reduce the frequency of vaso-occlusive crisis (VOC) in patients aged ≥16 years with sickle cell disease.
Modeling Lost Income and Life Expectancy Due to Sickle Cell Disease
Individuals with sickle cell disease were estimated to earn nearly $700,000 less over their lifetime compared with similar individuals without sickle cell disease.
Screening for Social Determinants of Health to Improve Care for Pediatric Sickle Cell Disease
Approximately two-thirds of patients who completed a screening questionnaire reported having at least 1 unmet socioeconomic need.
Incidence of Ischemic Stroke in Patients With Sickle Cell Disease on the STOP Protocol
Nearly two-thirds of ischemic strokes occurred in patients who had not properly completed the STOP protocol.
Missed Clinic Appointments Predictive of Hospital Admission and Readmission in Sickle Cell Disease
Depressive symptoms, spirituality, and missed clinic appointments were all found to correlate with hospital admission in sickle cell disease.
Study Investigating Rivipansel in Patients With Sickle Cell Disease Misses End Points
The primary end point was time to readiness for discharge, defined as the difference between the readiness-for-discharge date and time and the start date and time of the first infusion of study drug.
Crizanlizumab Granted Priority Review for Sickle Cell Pain Crises Prevention
Priority Review shortens the FDA review time from 10 months to 6 months
